SlideShare a Scribd company logo
1 of 62
ABETALIPOROTIENEMIA GROUP 3 Kavita Narula Arsenio Reblando Jinky Harvey Shila Lacia Dexcel Petty
Lipoproteins ,[object Object],[object Object],[object Object],[object Object],[object Object]
Lipoproteins
Lipoproteins ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Density  (g/m L ) Class Diameter (nm)   % protein   % cholesterol   % phospholipid   % triacylglycerol >1.063 HDL 5-15 33 30 29 8 1.019-1.063 LDL 18-28 25 50 21 4 1.006-1.019 IDL 25-50 18 29 22 31 0.95-1.006 VLDL 30-80 10 22 18 50 <0.95 Chylomicrons 100-1000 <2 8 7 84
Lipoproteins   ,[object Object],[object Object],[object Object],[object Object],[object Object]
Chylomicrons ,[object Object],[object Object],[object Object],[object Object],[object Object]
Chylomicrons ,[object Object],[object Object],[object Object],[object Object],[object Object]
Chylomicrons ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
VLDL ,[object Object],[object Object],[object Object],[object Object]
VLDL ,[object Object],[object Object],[object Object],[object Object],[object Object]
VLDL ,[object Object],[object Object],[object Object],[object Object],[object Object]
VLDL ,[object Object],[object Object],[object Object],[object Object]
VLDL ,[object Object],[object Object]
LDL ,[object Object],[object Object],[object Object],[object Object]
LDL ,[object Object],[object Object],[object Object]
LDL ,[object Object]
LDL ,[object Object]
LDL ,[object Object]
LDL ,[object Object],[object Object],[object Object],[object Object]
HDL ,[object Object],[object Object],[object Object],[object Object]
HDL ,[object Object],[object Object],[object Object],[object Object]
HDL ,[object Object],[object Object],[object Object],[object Object],[object Object]
HDL ,[object Object],[object Object],[object Object]
APOLIPOPROTIENS ,[object Object],[object Object],[object Object],[object Object],[object Object]
APOLIPOPROTIENS ,[object Object]
Apo E ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Apo A1 ,[object Object],[object Object],[object Object]
Apo B ,[object Object],[object Object],[object Object]
Apoproteins  ,[object Object],Apoprotein  Lipoprotein  Function  B48 CM Carry cholesterol esters B100 VLDL,IDL,LDL Binds LDL receptor C-II All Activate LPL C-III All Inhibit LPL Apo E CMremn., VLDL,IDL Binds remnant receptor Apo AI HDL,CM Activates L-CAT
3.  Review the transport of  lipids in the blood
Lipids Carried in Blood as Lipoproteins ••• ,[object Object],[object Object],[object Object]
Types of blood lipoproteins •  Chylomicron  (formed in cells of the small intestine) transfers dietary lipids from the intestine into the liver. •  VLDL  (formed in the liver) transfers lipids from the liver by blood to extra-hepatic tissues. •  IDL  (formed in circulation) is an intermediate LP of VLDL breakdown •  LDL  (formed in circulation) transfers lipids from blood into tissues. •  HDL  (formed in the liver and small intestine) transfers lipids from extra-hepatic locations to the liver.
[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object]
4. Define “abetalipoproteinemia”.  What is the underlying genetic  defect?
Abetalipoproteinemia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
5.  Why are the intestinal and hepatic cells accumulating fats in this disorder?  6.  What is its manifestations and possible complications?
[object Object]
[object Object],[object Object],[object Object],[object Object]
Signs and symptoms ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
7. Abetalipoproteinemia  is associated  with fat soluble vitamin deficiency. Explain this statement.
Abetalipoproteinemia is an inherited disorder that affects the absorption of dietary fats, cholesterol, and fat-soluble vitamins. People affected by this disorder are not able to make certain lipoproteins, which are particles that carry fats and fat-like substances (such as cholesterol) in the blood. Specifically, people with abetalipoproteinemia are missing a group of lipoproteins called beta-lipoproteins.
An inability to make beta-lipoproteins causes severely reduced absorption (malabsorption) of dietary fats and fat-soluble vitamins (vitamins A,  K, and E) from the digestive tract into the bloodstream. Sufficient levels of fats, cholesterol, and vitamins are necessary for normal growth, development, and maintenance of the body's cells and tissues, particularly nerve cells and tissues in the eye.
Patients with abetalipoproteinemia develop severe  vitamin E deficiency because they are defective in three steps in this pathway: First, along with other fat soluble vitamins, the fat malabsorption decreases the absorption of vitamin E  Second, the small amount of vitamin E that maybe absorbed can not be efficiently secreted by the intestine because of the defect in the chylomicron secretion. Third, any vitamin E that is delivered to the liver also can not be secreted because of the defect in the VLDL secretion
Vitamin A and K  Aare also packaged in to chylomicrons  after absorption from the lumen of the intestine, but unlike vitamin E , they have a separate transport system in the blood and are not dependent on VLDL for their transport.  Because the absorption of these vitamins  is affected only at steps 2 and 3. that’s why deficiency of these fat soluble vitamins are not severe.
8. Why do patients with This disorder  do not develop vitamin D  deficiency?
Vitamin D is a fat-soluble vitamin, meaning it is able to be dissolved in fat. While some vitamin D is supplied by the diet, most of it is made in the body. To make vitamin D, cholesterol, a sterol that is widely distributed in animal tissues and occurs in the yolk of eggs, as well as in various oils and fats, is necessary. Once cholesterol is available in the body, a slight alteration in the cholesterol molecule occurs, with one change taking place in the skin. This alteration requires the energy of sunlight (or ultraviolet light). Vitamin D deficiency, as well as rickets and osteomalacia, tends to occur in persons who do not get enough sunlight and who fail to eat foods that are rich in vitamin D.
Once consumed, or made in the body, vitamin D is further altered to produce a hormone called 1,25-dihy-droxy-vitamin D (1,25-diOH-D). The conversion of vitamin D to 1,25-diOH-D does not occur in the skin, but in the liver and kidney. First, vitamin D is converted to 25-OH-D in the liver; it then enters the bloodstream, where it is taken-up by the kidneys. At this point, it is converted to 1,25-diOH-D. Therefore, the manufacture of 1,25-diOH-D requires the participation of various organs of the body—the liver, kidney, and skin.
The purpose of 1,25-diOH-D in the body is to keep the concentration of calcium at a constant level in the bloodstream. The maintenance of calcium at a constant level is absolutely required for human life to exist, since dissolved calcium is required for nerves and muscles to work. One of the ways in which 1,25-diOH-D accomplishes this mission is by stimulating the absorption of dietary calcium by the intestines .
Approximately 80% is absorbed into the lymphatic system.  Vitamin D is bound to vitamin D-binding protein in the blood and  carried to the liver where it undergoes its first hydroxylation into 25-hydroxyvitamin D. This is then hydroxylated in the kidney into  1,25(OH)2D. When there is a calcium deficiency, parathyroid hormone is produced, which increases the tubular reabsorption of calcium and renal production of 1,25(OH)2D. The 1,25(OH)2D travels to the small intestine and increases the efficiency of calcium absorption. That is why vitamin D deficiency is not manifested in this disorder because it is not solely dependant on lipoproteins.
9. Aside from abetalipoproteinemia, what other disorders may arise from derangements of lipoprotein function? Discuss their genetic etiology and clinical manifestations.
[object Object],[object Object],[object Object],[object Object],[object Object]
Familial Dysbetalipoproteinemia ( Type III Hyperlipoproteinemia or familial broad B disease ,[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
Familial defective Apo B – 100( FDB) ,[object Object]
Familial Defective ApoB-100 ,[object Object],[object Object]
Autosomal recessive hypercholesterolemia ,[object Object],[object Object],[object Object],[object Object]
Sitosterolemia ,[object Object],[object Object],[object Object],[object Object]
[object Object]

More Related Content

What's hot

LIPOPROTEINEMIAS OR DYSLIPIDEMIA
LIPOPROTEINEMIAS OR DYSLIPIDEMIALIPOPROTEINEMIAS OR DYSLIPIDEMIA
LIPOPROTEINEMIAS OR DYSLIPIDEMIAYESANNA
 
ALCOHOL METABOLISM
ALCOHOL METABOLISMALCOHOL METABOLISM
ALCOHOL METABOLISMYESANNA
 
Familial hypercholestrolemia
Familial hypercholestrolemiaFamilial hypercholestrolemia
Familial hypercholestrolemiapromotemedical
 
Lastose and fructose intolerance
Lastose and fructose intoleranceLastose and fructose intolerance
Lastose and fructose intoleranceSugandhinatatajan
 
Lipoproteins: Structure, classification, metabolism and significance
Lipoproteins:  Structure, classification, metabolism and significanceLipoproteins:  Structure, classification, metabolism and significance
Lipoproteins: Structure, classification, metabolism and significanceenamifat
 
DISORDER OF LIPIDS METABOLISM PART 1.pptx
DISORDER OF LIPIDS METABOLISM PART 1.pptxDISORDER OF LIPIDS METABOLISM PART 1.pptx
DISORDER OF LIPIDS METABOLISM PART 1.pptxMkindi Mkindi
 
Lipoproteins- structure, classification, metabolism and clinical significance
Lipoproteins- structure, classification, metabolism and clinical significanceLipoproteins- structure, classification, metabolism and clinical significance
Lipoproteins- structure, classification, metabolism and clinical significanceNamrata Chhabra
 
All about "Lipid metabolism" - case-based discussions and multiple- -choice q...
All about "Lipid metabolism" - case-based discussions and multiple- -choice q...All about "Lipid metabolism" - case-based discussions and multiple- -choice q...
All about "Lipid metabolism" - case-based discussions and multiple- -choice q...Namrata Chhabra
 
LDL & HDL METABOLISM
LDL & HDL METABOLISMLDL & HDL METABOLISM
LDL & HDL METABOLISMYESANNA
 
Apolipoprotein and their function, chromium as muscle building tissue and rel...
Apolipoprotein and their function, chromium as muscle building tissue and rel...Apolipoprotein and their function, chromium as muscle building tissue and rel...
Apolipoprotein and their function, chromium as muscle building tissue and rel...preeti bartwal
 
Metabolism of lipoproteins
Metabolism of lipoproteinsMetabolism of lipoproteins
Metabolism of lipoproteinsRamesh Gupta
 
Disorders of lipid metabolism ppt
Disorders of lipid metabolism pptDisorders of lipid metabolism ppt
Disorders of lipid metabolism pptAhmed Al Sa'idi
 
Albumin and albumin & globin ratio
Albumin and albumin & globin ratioAlbumin and albumin & globin ratio
Albumin and albumin & globin ratioPrakash Mishra
 
Disorders of Lipoprotein Metabolism
Disorders of Lipoprotein MetabolismDisorders of Lipoprotein Metabolism
Disorders of Lipoprotein MetabolismASHIKH SEETHY
 
metabolism of LDL, IDL and HDL
metabolism of LDL, IDL and HDLmetabolism of LDL, IDL and HDL
metabolism of LDL, IDL and HDLASHWATHI GOVIND
 

What's hot (20)

Lipid disorders
Lipid disorders Lipid disorders
Lipid disorders
 
Alkaptonuria
AlkaptonuriaAlkaptonuria
Alkaptonuria
 
LIPOPROTEINEMIAS OR DYSLIPIDEMIA
LIPOPROTEINEMIAS OR DYSLIPIDEMIALIPOPROTEINEMIAS OR DYSLIPIDEMIA
LIPOPROTEINEMIAS OR DYSLIPIDEMIA
 
ALCOHOL METABOLISM
ALCOHOL METABOLISMALCOHOL METABOLISM
ALCOHOL METABOLISM
 
Alkaptonuria
AlkaptonuriaAlkaptonuria
Alkaptonuria
 
Familial hypercholestrolemia
Familial hypercholestrolemiaFamilial hypercholestrolemia
Familial hypercholestrolemia
 
Lastose and fructose intolerance
Lastose and fructose intoleranceLastose and fructose intolerance
Lastose and fructose intolerance
 
Lipoproteins: Structure, classification, metabolism and significance
Lipoproteins:  Structure, classification, metabolism and significanceLipoproteins:  Structure, classification, metabolism and significance
Lipoproteins: Structure, classification, metabolism and significance
 
DISORDER OF LIPIDS METABOLISM PART 1.pptx
DISORDER OF LIPIDS METABOLISM PART 1.pptxDISORDER OF LIPIDS METABOLISM PART 1.pptx
DISORDER OF LIPIDS METABOLISM PART 1.pptx
 
Lipoproteins- structure, classification, metabolism and clinical significance
Lipoproteins- structure, classification, metabolism and clinical significanceLipoproteins- structure, classification, metabolism and clinical significance
Lipoproteins- structure, classification, metabolism and clinical significance
 
All about "Lipid metabolism" - case-based discussions and multiple- -choice q...
All about "Lipid metabolism" - case-based discussions and multiple- -choice q...All about "Lipid metabolism" - case-based discussions and multiple- -choice q...
All about "Lipid metabolism" - case-based discussions and multiple- -choice q...
 
LDL & HDL METABOLISM
LDL & HDL METABOLISMLDL & HDL METABOLISM
LDL & HDL METABOLISM
 
Apolipoprotein and their function, chromium as muscle building tissue and rel...
Apolipoprotein and their function, chromium as muscle building tissue and rel...Apolipoprotein and their function, chromium as muscle building tissue and rel...
Apolipoprotein and their function, chromium as muscle building tissue and rel...
 
Metabolism of lipoproteins
Metabolism of lipoproteinsMetabolism of lipoproteins
Metabolism of lipoproteins
 
Disorders of lipid metabolism ppt
Disorders of lipid metabolism pptDisorders of lipid metabolism ppt
Disorders of lipid metabolism ppt
 
Albumin and albumin & globin ratio
Albumin and albumin & globin ratioAlbumin and albumin & globin ratio
Albumin and albumin & globin ratio
 
Sphingolipidoses
Sphingolipidoses Sphingolipidoses
Sphingolipidoses
 
Metabolism of Vitamin B12 and Folic Acid
Metabolism of Vitamin B12 and Folic Acid Metabolism of Vitamin B12 and Folic Acid
Metabolism of Vitamin B12 and Folic Acid
 
Disorders of Lipoprotein Metabolism
Disorders of Lipoprotein MetabolismDisorders of Lipoprotein Metabolism
Disorders of Lipoprotein Metabolism
 
metabolism of LDL, IDL and HDL
metabolism of LDL, IDL and HDLmetabolism of LDL, IDL and HDL
metabolism of LDL, IDL and HDL
 

Viewers also liked (20)

Refsum Disease
Refsum DiseaseRefsum Disease
Refsum Disease
 
Abetalipoproteinemia
AbetalipoproteinemiaAbetalipoproteinemia
Abetalipoproteinemia
 
Citazioni e author identifiers
Citazioni e author identifiersCitazioni e author identifiers
Citazioni e author identifiers
 
Lipids
LipidsLipids
Lipids
 
Refsum disease
Refsum diseaseRefsum disease
Refsum disease
 
Progressive myoclonic epilepsy
Progressive myoclonic epilepsyProgressive myoclonic epilepsy
Progressive myoclonic epilepsy
 
Syndromes
SyndromesSyndromes
Syndromes
 
1 lipoproteins
1   lipoproteins1   lipoproteins
1 lipoproteins
 
Nyctalopia & retinitis pigmentosa
Nyctalopia  &  retinitis pigmentosaNyctalopia  &  retinitis pigmentosa
Nyctalopia & retinitis pigmentosa
 
Abordaje de anemia
Abordaje de anemiaAbordaje de anemia
Abordaje de anemia
 
Fleck retina dr zeeshan
Fleck retina dr zeeshanFleck retina dr zeeshan
Fleck retina dr zeeshan
 
Anemia
AnemiaAnemia
Anemia
 
Nw2016 retinitis pigmentosa
Nw2016 retinitis pigmentosaNw2016 retinitis pigmentosa
Nw2016 retinitis pigmentosa
 
دستگاه گوارش
دستگاه گوارشدستگاه گوارش
دستگاه گوارش
 
Retinosis pigmentaria
Retinosis pigmentariaRetinosis pigmentaria
Retinosis pigmentaria
 
Case presentation-Retinitis Pigmentosa Albecanse
Case presentation-Retinitis Pigmentosa AlbecanseCase presentation-Retinitis Pigmentosa Albecanse
Case presentation-Retinitis Pigmentosa Albecanse
 
Retinitis Pigmentaria
Retinitis Pigmentaria  Retinitis Pigmentaria
Retinitis Pigmentaria
 
Retinitis pigmentosa
Retinitis pigmentosaRetinitis pigmentosa
Retinitis pigmentosa
 
Myoclonus
MyoclonusMyoclonus
Myoclonus
 
MACULAR DYSTROPHIES
MACULAR DYSTROPHIESMACULAR DYSTROPHIES
MACULAR DYSTROPHIES
 

Similar to Abetalipoprotienemia..Final..group 3

lipoprotein metabolism.pptx HDL METABOLISM, LDL METABOLIS, VLDL METABOLIS, C...
lipoprotein metabolism.pptx  HDL METABOLISM, LDL METABOLIS, VLDL METABOLIS, C...lipoprotein metabolism.pptx  HDL METABOLISM, LDL METABOLIS, VLDL METABOLIS, C...
lipoprotein metabolism.pptx HDL METABOLISM, LDL METABOLIS, VLDL METABOLIS, C...binaya tamang
 
Lipid metabolism
Lipid metabolismLipid metabolism
Lipid metabolismEtikaSaxena
 
Lipoprotein metabolism
Lipoprotein metabolismLipoprotein metabolism
Lipoprotein metabolismSohil Takodara
 
Abnormalities in lipoproteinemia
Abnormalities in  lipoproteinemiaAbnormalities in  lipoproteinemia
Abnormalities in lipoproteinemiaPranatiChavan
 
8-LIPOPROTEIN METABOLISM.ppt
8-LIPOPROTEIN METABOLISM.ppt8-LIPOPROTEIN METABOLISM.ppt
8-LIPOPROTEIN METABOLISM.pptFATIMAMIRZA27
 
metabolismoflipoproteins-170224153001 2.pdf
metabolismoflipoproteins-170224153001 2.pdfmetabolismoflipoproteins-170224153001 2.pdf
metabolismoflipoproteins-170224153001 2.pdfAnukrittiMehra
 
Metabolism of lipoproteins
Metabolism of lipoproteinsMetabolism of lipoproteins
Metabolism of lipoproteinssreelakshmi k v
 
Abnormalities in Lipoproteinemia
Abnormalities in Lipoproteinemia Abnormalities in Lipoproteinemia
Abnormalities in Lipoproteinemia Jaineel Dharod
 
Lipoproteins and their metabolism
Lipoproteins and their metabolismLipoproteins and their metabolism
Lipoproteins and their metabolismMadihaAsad5
 
1.+Antihyperlipidemic+drugs+FrK.pptx
1.+Antihyperlipidemic+drugs+FrK.pptx1.+Antihyperlipidemic+drugs+FrK.pptx
1.+Antihyperlipidemic+drugs+FrK.pptxTahsinAhmed32
 
3 lipid transport jihs
3 lipid transport jihs3 lipid transport jihs
3 lipid transport jihsSimon Angok
 
Lipo proteins 2
Lipo proteins 2Lipo proteins 2
Lipo proteins 2Ali iqbal
 
3- Lipoprotein Metabolism-2018.pptx
3- Lipoprotein Metabolism-2018.pptx3- Lipoprotein Metabolism-2018.pptx
3- Lipoprotein Metabolism-2018.pptxLightOzioma
 

Similar to Abetalipoprotienemia..Final..group 3 (20)

Lipid transport 2020
Lipid transport 2020Lipid transport 2020
Lipid transport 2020
 
lipoprotein metabolism.pptx HDL METABOLISM, LDL METABOLIS, VLDL METABOLIS, C...
lipoprotein metabolism.pptx  HDL METABOLISM, LDL METABOLIS, VLDL METABOLIS, C...lipoprotein metabolism.pptx  HDL METABOLISM, LDL METABOLIS, VLDL METABOLIS, C...
lipoprotein metabolism.pptx HDL METABOLISM, LDL METABOLIS, VLDL METABOLIS, C...
 
Lipoprotein Metabolism.pptx
Lipoprotein Metabolism.pptxLipoprotein Metabolism.pptx
Lipoprotein Metabolism.pptx
 
Lipoproteins
LipoproteinsLipoproteins
Lipoproteins
 
Lipid metabolism
Lipid metabolismLipid metabolism
Lipid metabolism
 
Lipoprotein metabolism
Lipoprotein metabolismLipoprotein metabolism
Lipoprotein metabolism
 
Abnormalities in lipoproteinemia
Abnormalities in  lipoproteinemiaAbnormalities in  lipoproteinemia
Abnormalities in lipoproteinemia
 
8-LIPOPROTEIN METABOLISM.ppt
8-LIPOPROTEIN METABOLISM.ppt8-LIPOPROTEIN METABOLISM.ppt
8-LIPOPROTEIN METABOLISM.ppt
 
metabolismoflipoproteins-170224153001 2.pdf
metabolismoflipoproteins-170224153001 2.pdfmetabolismoflipoproteins-170224153001 2.pdf
metabolismoflipoproteins-170224153001 2.pdf
 
Metabolism of lipoproteins
Metabolism of lipoproteinsMetabolism of lipoproteins
Metabolism of lipoproteins
 
lipoprotein
 lipoprotein lipoprotein
lipoprotein
 
Abnormalities in Lipoproteinemia
Abnormalities in Lipoproteinemia Abnormalities in Lipoproteinemia
Abnormalities in Lipoproteinemia
 
HYPERLIPIDEMIA
HYPERLIPIDEMIAHYPERLIPIDEMIA
HYPERLIPIDEMIA
 
Lipoproteins and their metabolism
Lipoproteins and their metabolismLipoproteins and their metabolism
Lipoproteins and their metabolism
 
1.+Antihyperlipidemic+drugs+FrK.pptx
1.+Antihyperlipidemic+drugs+FrK.pptx1.+Antihyperlipidemic+drugs+FrK.pptx
1.+Antihyperlipidemic+drugs+FrK.pptx
 
3 lipid transport jihs
3 lipid transport jihs3 lipid transport jihs
3 lipid transport jihs
 
Lipo proteins 2
Lipo proteins 2Lipo proteins 2
Lipo proteins 2
 
lpp.pptx
lpp.pptxlpp.pptx
lpp.pptx
 
3- Lipoprotein Metabolism-2018.pptx
3- Lipoprotein Metabolism-2018.pptx3- Lipoprotein Metabolism-2018.pptx
3- Lipoprotein Metabolism-2018.pptx
 
CVS lipoprotein metabolism, .pptx
CVS lipoprotein metabolism, .pptxCVS lipoprotein metabolism, .pptx
CVS lipoprotein metabolism, .pptx
 

More from MD Specialclass

Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...MD Specialclass
 
Git diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionGit diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionMD Specialclass
 
Getting ahead of headaches
Getting ahead of headachesGetting ahead of headaches
Getting ahead of headachesMD Specialclass
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL MD Specialclass
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL MD Specialclass
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinomaMD Specialclass
 
Normal sleep and sleep disorders
Normal sleep and sleep disordersNormal sleep and sleep disorders
Normal sleep and sleep disordersMD Specialclass
 
Toxic and drug induced hepatitis
Toxic and drug induced hepatitisToxic and drug induced hepatitis
Toxic and drug induced hepatitisMD Specialclass
 
Complications of cirrhosis
Complications of cirrhosisComplications of cirrhosis
Complications of cirrhosisMD Specialclass
 

More from MD Specialclass (20)

Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
 
Git diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionGit diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutrition
 
Getting ahead of headaches
Getting ahead of headachesGetting ahead of headaches
Getting ahead of headaches
 
Acute brain attack 911
Acute brain attack  911Acute brain attack  911
Acute brain attack 911
 
Hema intro anemia
Hema intro anemiaHema intro anemia
Hema intro anemia
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL
 
Fever & id diet final
Fever & id diet finalFever & id diet final
Fever & id diet final
 
Eating disorders
Eating disordersEating disorders
Eating disorders
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinoma
 
Eating disorders
Eating disordersEating disorders
Eating disorders
 
Normal sleep and sleep disorders
Normal sleep and sleep disordersNormal sleep and sleep disorders
Normal sleep and sleep disorders
 
Tic disorder
Tic disorderTic disorder
Tic disorder
 
Thyroid
ThyroidThyroid
Thyroid
 
Dermatology dr.n.ramos
Dermatology   dr.n.ramosDermatology   dr.n.ramos
Dermatology dr.n.ramos
 
Tic disorder
Tic disorderTic disorder
Tic disorder
 
Toxic and drug induced hepatitis
Toxic and drug induced hepatitisToxic and drug induced hepatitis
Toxic and drug induced hepatitis
 
Pancreatic disease
Pancreatic diseasePancreatic disease
Pancreatic disease
 
Liver disease
Liver diseaseLiver disease
Liver disease
 
Complications of cirrhosis
Complications of cirrhosisComplications of cirrhosis
Complications of cirrhosis
 

Recently uploaded

State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!Memoori
 
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...panagenda
 
Continuing Bonds Through AI: A Hermeneutic Reflection on Thanabots
Continuing Bonds Through AI: A Hermeneutic Reflection on ThanabotsContinuing Bonds Through AI: A Hermeneutic Reflection on Thanabots
Continuing Bonds Through AI: A Hermeneutic Reflection on ThanabotsLeah Henrickson
 
TopCryptoSupers 12thReport OrionX May2024
TopCryptoSupers 12thReport OrionX May2024TopCryptoSupers 12thReport OrionX May2024
TopCryptoSupers 12thReport OrionX May2024Stephen Perrenod
 
UiPath manufacturing technology benefits and AI overview
UiPath manufacturing technology benefits and AI overviewUiPath manufacturing technology benefits and AI overview
UiPath manufacturing technology benefits and AI overviewDianaGray10
 
Design Guidelines for Passkeys 2024.pptx
Design Guidelines for Passkeys 2024.pptxDesign Guidelines for Passkeys 2024.pptx
Design Guidelines for Passkeys 2024.pptxFIDO Alliance
 
How we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfHow we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfSrushith Repakula
 
Google I/O Extended 2024 Warsaw
Google I/O Extended 2024 WarsawGoogle I/O Extended 2024 Warsaw
Google I/O Extended 2024 WarsawGDSC PJATK
 
Portal Kombat : extension du réseau de propagande russe
Portal Kombat : extension du réseau de propagande russePortal Kombat : extension du réseau de propagande russe
Portal Kombat : extension du réseau de propagande russe中 央社
 
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...FIDO Alliance
 
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...FIDO Alliance
 
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdfSimplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdfFIDO Alliance
 
Long journey of Ruby Standard library at RubyKaigi 2024
Long journey of Ruby Standard library at RubyKaigi 2024Long journey of Ruby Standard library at RubyKaigi 2024
Long journey of Ruby Standard library at RubyKaigi 2024Hiroshi SHIBATA
 
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...FIDO Alliance
 
2024 May Patch Tuesday
2024 May Patch Tuesday2024 May Patch Tuesday
2024 May Patch TuesdayIvanti
 
The Zero-ETL Approach: Enhancing Data Agility and Insight
The Zero-ETL Approach: Enhancing Data Agility and InsightThe Zero-ETL Approach: Enhancing Data Agility and Insight
The Zero-ETL Approach: Enhancing Data Agility and InsightSafe Software
 
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdfMuhammad Subhan
 
Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...
Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...
Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...ScyllaDB
 
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdfIntroduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdfFIDO Alliance
 
Event-Driven Architecture Masterclass: Challenges in Stream Processing
Event-Driven Architecture Masterclass: Challenges in Stream ProcessingEvent-Driven Architecture Masterclass: Challenges in Stream Processing
Event-Driven Architecture Masterclass: Challenges in Stream ProcessingScyllaDB
 

Recently uploaded (20)

State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!
 
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
 
Continuing Bonds Through AI: A Hermeneutic Reflection on Thanabots
Continuing Bonds Through AI: A Hermeneutic Reflection on ThanabotsContinuing Bonds Through AI: A Hermeneutic Reflection on Thanabots
Continuing Bonds Through AI: A Hermeneutic Reflection on Thanabots
 
TopCryptoSupers 12thReport OrionX May2024
TopCryptoSupers 12thReport OrionX May2024TopCryptoSupers 12thReport OrionX May2024
TopCryptoSupers 12thReport OrionX May2024
 
UiPath manufacturing technology benefits and AI overview
UiPath manufacturing technology benefits and AI overviewUiPath manufacturing technology benefits and AI overview
UiPath manufacturing technology benefits and AI overview
 
Design Guidelines for Passkeys 2024.pptx
Design Guidelines for Passkeys 2024.pptxDesign Guidelines for Passkeys 2024.pptx
Design Guidelines for Passkeys 2024.pptx
 
How we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfHow we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdf
 
Google I/O Extended 2024 Warsaw
Google I/O Extended 2024 WarsawGoogle I/O Extended 2024 Warsaw
Google I/O Extended 2024 Warsaw
 
Portal Kombat : extension du réseau de propagande russe
Portal Kombat : extension du réseau de propagande russePortal Kombat : extension du réseau de propagande russe
Portal Kombat : extension du réseau de propagande russe
 
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
 
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
 
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdfSimplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
 
Long journey of Ruby Standard library at RubyKaigi 2024
Long journey of Ruby Standard library at RubyKaigi 2024Long journey of Ruby Standard library at RubyKaigi 2024
Long journey of Ruby Standard library at RubyKaigi 2024
 
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
 
2024 May Patch Tuesday
2024 May Patch Tuesday2024 May Patch Tuesday
2024 May Patch Tuesday
 
The Zero-ETL Approach: Enhancing Data Agility and Insight
The Zero-ETL Approach: Enhancing Data Agility and InsightThe Zero-ETL Approach: Enhancing Data Agility and Insight
The Zero-ETL Approach: Enhancing Data Agility and Insight
 
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
 
Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...
Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...
Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...
 
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdfIntroduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
 
Event-Driven Architecture Masterclass: Challenges in Stream Processing
Event-Driven Architecture Masterclass: Challenges in Stream ProcessingEvent-Driven Architecture Masterclass: Challenges in Stream Processing
Event-Driven Architecture Masterclass: Challenges in Stream Processing
 

Abetalipoprotienemia..Final..group 3

  • 1. ABETALIPOROTIENEMIA GROUP 3 Kavita Narula Arsenio Reblando Jinky Harvey Shila Lacia Dexcel Petty
  • 2.
  • 4.
  • 5. Density (g/m L ) Class Diameter (nm)   % protein   % cholesterol   % phospholipid   % triacylglycerol >1.063 HDL 5-15 33 30 29 8 1.019-1.063 LDL 18-28 25 50 21 4 1.006-1.019 IDL 25-50 18 29 22 31 0.95-1.006 VLDL 30-80 10 22 18 50 <0.95 Chylomicrons 100-1000 <2 8 7 84
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31. 3. Review the transport of lipids in the blood
  • 32.
  • 33. Types of blood lipoproteins • Chylomicron (formed in cells of the small intestine) transfers dietary lipids from the intestine into the liver. • VLDL (formed in the liver) transfers lipids from the liver by blood to extra-hepatic tissues. • IDL (formed in circulation) is an intermediate LP of VLDL breakdown • LDL (formed in circulation) transfers lipids from blood into tissues. • HDL (formed in the liver and small intestine) transfers lipids from extra-hepatic locations to the liver.
  • 34.
  • 35.
  • 36.
  • 37. 4. Define “abetalipoproteinemia”. What is the underlying genetic defect?
  • 38.
  • 39.
  • 40. 5. Why are the intestinal and hepatic cells accumulating fats in this disorder? 6. What is its manifestations and possible complications?
  • 41.
  • 42.
  • 43.
  • 44. 7. Abetalipoproteinemia is associated with fat soluble vitamin deficiency. Explain this statement.
  • 45. Abetalipoproteinemia is an inherited disorder that affects the absorption of dietary fats, cholesterol, and fat-soluble vitamins. People affected by this disorder are not able to make certain lipoproteins, which are particles that carry fats and fat-like substances (such as cholesterol) in the blood. Specifically, people with abetalipoproteinemia are missing a group of lipoproteins called beta-lipoproteins.
  • 46. An inability to make beta-lipoproteins causes severely reduced absorption (malabsorption) of dietary fats and fat-soluble vitamins (vitamins A, K, and E) from the digestive tract into the bloodstream. Sufficient levels of fats, cholesterol, and vitamins are necessary for normal growth, development, and maintenance of the body's cells and tissues, particularly nerve cells and tissues in the eye.
  • 47. Patients with abetalipoproteinemia develop severe vitamin E deficiency because they are defective in three steps in this pathway: First, along with other fat soluble vitamins, the fat malabsorption decreases the absorption of vitamin E Second, the small amount of vitamin E that maybe absorbed can not be efficiently secreted by the intestine because of the defect in the chylomicron secretion. Third, any vitamin E that is delivered to the liver also can not be secreted because of the defect in the VLDL secretion
  • 48. Vitamin A and K Aare also packaged in to chylomicrons after absorption from the lumen of the intestine, but unlike vitamin E , they have a separate transport system in the blood and are not dependent on VLDL for their transport. Because the absorption of these vitamins is affected only at steps 2 and 3. that’s why deficiency of these fat soluble vitamins are not severe.
  • 49. 8. Why do patients with This disorder do not develop vitamin D deficiency?
  • 50. Vitamin D is a fat-soluble vitamin, meaning it is able to be dissolved in fat. While some vitamin D is supplied by the diet, most of it is made in the body. To make vitamin D, cholesterol, a sterol that is widely distributed in animal tissues and occurs in the yolk of eggs, as well as in various oils and fats, is necessary. Once cholesterol is available in the body, a slight alteration in the cholesterol molecule occurs, with one change taking place in the skin. This alteration requires the energy of sunlight (or ultraviolet light). Vitamin D deficiency, as well as rickets and osteomalacia, tends to occur in persons who do not get enough sunlight and who fail to eat foods that are rich in vitamin D.
  • 51. Once consumed, or made in the body, vitamin D is further altered to produce a hormone called 1,25-dihy-droxy-vitamin D (1,25-diOH-D). The conversion of vitamin D to 1,25-diOH-D does not occur in the skin, but in the liver and kidney. First, vitamin D is converted to 25-OH-D in the liver; it then enters the bloodstream, where it is taken-up by the kidneys. At this point, it is converted to 1,25-diOH-D. Therefore, the manufacture of 1,25-diOH-D requires the participation of various organs of the body—the liver, kidney, and skin.
  • 52. The purpose of 1,25-diOH-D in the body is to keep the concentration of calcium at a constant level in the bloodstream. The maintenance of calcium at a constant level is absolutely required for human life to exist, since dissolved calcium is required for nerves and muscles to work. One of the ways in which 1,25-diOH-D accomplishes this mission is by stimulating the absorption of dietary calcium by the intestines .
  • 53. Approximately 80% is absorbed into the lymphatic system. Vitamin D is bound to vitamin D-binding protein in the blood and carried to the liver where it undergoes its first hydroxylation into 25-hydroxyvitamin D. This is then hydroxylated in the kidney into 1,25(OH)2D. When there is a calcium deficiency, parathyroid hormone is produced, which increases the tubular reabsorption of calcium and renal production of 1,25(OH)2D. The 1,25(OH)2D travels to the small intestine and increases the efficiency of calcium absorption. That is why vitamin D deficiency is not manifested in this disorder because it is not solely dependant on lipoproteins.
  • 54. 9. Aside from abetalipoproteinemia, what other disorders may arise from derangements of lipoprotein function? Discuss their genetic etiology and clinical manifestations.
  • 55.
  • 56.
  • 57.
  • 58.
  • 59.
  • 60.
  • 61.
  • 62.